AI Is Not Ready to Be the Decision-Maker, And Pretending Otherwise Is the Real Risk
The industry's AI rhetoric has outrun its AI maturity by several years, and the gap is being covered up with confidence …
At Scimitar, Akira Robinson serves as Partner, Commercialization. He operates at the intersection of commercial strategy, launch execution, and market access, advising biopharma executive teams at critical moments where launch readiness directly determines asset value and time to market. With 20 years of experience across life sciences, diagnostics, biologics, and digital medicine, his work tackles complex commercial challenges for teams across the US and globally. His expertise spans the full commercial value chain—including launch planning, licensing, market access, pricing, analytics, marketing, sales distribution, and patient services across therapy areas, including: oncology, radiopharmaceuticals (RLT), rare disease, CNS, cardiology, and gastroenterology.